Ulf G. Eriksson
AstraZeneca R&D Mölndal
Sweden
Name/email consistency: high
- Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. Eriksson, U.G., Dorani, H., Karlsson, J., Fritsch, H., Hoffmann, K.J., Olsson, L., Sarich, T.C., Wall, U., Schützer, K.M. Drug Metab. Dispos. (2006)
- Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Eriksson, U.G., Bredberg, U., Hoffmann, K.J., Thuresson, A., Gabrielsson, M., Ericsson, H., Ahnoff, M., Gislén, K., Fager, G., Gustafsson, D. Drug Metab. Dispos. (2003)
- Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eriksson, U.G., Bredberg, U., Gislén, K., Johansson, L.C., Frison, L., Ahnoff, M., Gustafsson, D. Eur. J. Clin. Pharmacol. (2003)
- Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Eriksson, U.G., Mandema, J.W., Karlsson, M.O., Frison, L., Gisleskog, P.O., Wählby, U., Hamrén, B., Gustafsson, D., Eriksson, B.I. Clin. Pharmacokinet (2003)
- Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Eriksson, U.G., Johansson, S., Attman, P.O., Mulec, H., Frison, L., Fager, G., Samuelsson, O. Clin. Pharmacokinet (2003)
